A study to investigate patritumab in combination with cetuximab plus platinum-containing therapies in patients with head and neck cancer

Registry ID

EUCTR2015-002222-40

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Daiichi Sankyo , Inc.

Start date

2015-09-22

Completion date

2018-02-21

Last update

2026-08-16

Conditions

• Squamous Cell Carcinoma of the Head and Neck

Summary

• To evaluate progression-free survival (PFS) in the heregulin (HRG) high expression population from subjects treated with patritumab + cetuximab + platinum-based therapy compared to placebo + cetuximab + platinum-based therapy.

Locations

• , , Belgium
• , , Germany
• , , Hungary
• , , UK

Related clinical trials

• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
• Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
• Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
• Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
• Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
• Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

View on source registry